DNX-2401 regulatory update

EMA granted PRIority MEdicines (PRIME) designation to DNX-2401 from DNAtrix to treat recurrent glioblastoma. The company said in “the coming weeks” it will begin a Phase II trial evaluating DNX-2401 i...